Johnson & Johnson news

   Watch this stock
Showing stories 11 - 20 of about 118   

Articles published

JNJ 101.22 +0.86 (0.86%)
price chart
One Put, One Call Option To Know About for Johnson & Johnson
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Johnson & Johnson JNJ -0.24% (NYSE: JNJ). So this week we highlight one interesting put contract, and one interesting call contract ...
Related articles »  
J&J sales top forecast, helped by drug for hep C
At the end of September, Johnson & Johnson announced plans to buy Alios BioPharma, a biotech company focused on developing existing therapies for viral diseases.
Why I'm in Johnson & Johnson for the long run  The Globe and Mail
Gilead Retreats Following Johnson & Johnson Comments On HCV Drug  TheStreet.com
Related articles »  
Johnson & Johnson Announces Major Commitment to Speed Ebola Vaccine ...
NEW BRUNSWICK, N.J., Oct. 22, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that it has made a commitment of up to $200 million to accelerate and significantly expand the production of an Ebola vaccine program in ...
Why Johnson & Johnson (JNJ) Stock Is Up Today
NEW YORK (TheStreet) -- Johnson & Johnson (JNJ) shares are higher by 0.45% to $97.44 after the company reported third quarter net income of $4.7 billion, or $1.66 per diluted share, compared to $2.9 billion, or $1.04 per diluted share, for the same ...
Johnson & Johnson Earnings: Pharmaceutical Sales Again Lead the Way  Motley Fool
J&J's revenue up, but near flat sales growth in medical devices ...  Philly.com (blog)
Related articles »  
Johnson & Johnson Earnings Preview: Pharma Is Where The Party Is
This year has been eventful for Johnson & Johnson. The company completed the divestiture of Ortho-Clinical Diagnostics to Carlyle Group in Q3 2014 and got the approval for its new blockbuster drug Olysio in Europe in the second quarter.
Related articles »  
#PreMarket Primer: Wednesday, October 22: Johnson & Johnson Develops ...
Johnson & Johnson (NYSE: JNJ) has developed a vaccine to fight Ebola and will begin testing the drug on humans in January.
The Biggest Threat Facing Johnson & Johnson
Johnson & Johnson (NYSE: JNJ ) is one of the globe's biggest healthcare companies. Its businesses include everything from Band-Aids to catheters, to cancer busting compounds.
Johnson & Johnson's Growth Potential Is Stronger Than You Think (JNJ)  Seeking Alpha (registration)
Related articles »  
Why Johnson & Johnson (JNJ) Stock Is Climbing Today
Johnson & Johnson is one of the biggest health care companies in the world, and has interests in pharmaceuticals, medical devices, and consumer diagnostics with It's s a number of well known brands in its product portfolio including Johnson's baby ...
What to expect from Johnson & Johnson's earnings
Johnson & Johnson, the shares of which have been among the better year-to-date performers of components of the Dow Jones Industrial Average, is scheduled to report third-quarter results ahead of Tuesday's open.
Johnson & Johnson Takes Aim at Gilead Sciences, inc.
Johnson & Johnson (NYSE: JNJ ) doesn't typically like to play second fiddle to anyone, particularly when billions of dollars in drug sales are at stake.
Related articles »